drugset / Trial / NCT05952089

A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure

NCT05952089

Phase 1 Completed 13 enrolled Bristol-Myers Squibb
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is assess the effect of danicamtiv, as an inducer on the drug levels of midazolam in participants with heart failure with reduced ejection fraction (HFrEF).

Timeline

Start
2023-08-17
Primary completion
2024-03-15
Completion
2024-03-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Danicamtiv Small molecule
Subject Midazolam Small molecule